Study of BMS-986158 in Subjects With Select Advanced Cancers

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02419417

Acronym

BET

Enrollment

Registered

2015-04-17

Start date

2015-06-19

Completion date

2021-03-17

Last updated

2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Tumors

Brief summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Interventions

DRUGBMS-986158

Specified dose on specified days

BIOLOGICALNivolumab

Specified dose on specified days

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have select advanced cancers with specific genetic profiles * Must have received appropriate standard of care * At least one measurable lesion at baseline * Expected to have life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion criteria

* Concomitant second malignancies * Uncontrolled or significant cardiovascular disease * Inadequate bone marrow function * Chronic gastrointestinal illness * Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor Other protocol defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants Experiencing Adverse Events	From first dose to 30 days following last dose (up to approximately 29 months)	Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths. Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Number of Participants With Abnormal Hepatic Test Values	From first dose to 30 days following last dose (up to approximately 29 months)	Number of participants experiencing abnormal hepatic function, as measured by different parameters. ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal

Secondary

Measure	Time frame	Description
Best Overall Response (BOR)	From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)	BOR, as assessed by the investigator, is defined as the best response designation, recorded between the dates of first dose and the date of first objectively documented progression (per RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies or PCWG3 for prostate cancer) or the date of subsequent therapy, whichever occurs first.
Objective Response Rate (ORR)	From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)	ORR is defined as the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR)
Duration of Response (DOR)	From date of first response to date of first objectively documented disease progression or death (up to approximately 42 weeks)	DOR is defined as the time between the date of first response and the date of the first objectively documented disease progression (as determined by RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies, or PCWG3 (including PSA assessments) for prostate cancer \[CRPC or NEPC\]), or death due to any cause, whichever occurs first.
Progression Free Survival (PFS)	From first dose to date of first objectively documented disease progression or death (up to approximately 28 months)	PFS is defined as the time from the first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause.
Progression Free Survival Rate (PFSR)	From first dose to 12 weeks, to 24 weeks, and to 48 weeks after first dose	PFSR is defined as the percentage of participants who remain progression free and surviving at the specified timepoints (12 weeks, 24 weeks, and 48 weeks). Reported values are estimates derived from Kaplan-Meier analyses
Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485
Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485
Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485
Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485
Apparent Total Body Clearance (CLT/F) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported only for the parent BMS-986158
Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	From drug administration in Cycle 1 Day 1 to 168 hours post drug administration	Values are reported only for the parent BMS-986158
Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are reported only for the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	From Cycle (C)2 Day (D)2 to C2D5 (Schedule A) or from C2D14 to C4D8 (Schedule B) or from C2D7 to C8D8 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for the first and last collection
Accumulation Index (AI) - Multiple Dose Administration	Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)	AI is defined as the ratio of an exposure measure at steady-state to that after the first dose. Reported exposure measures include Cmax, C24 and AUC24. Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.
Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)	Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.
Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	Cycle 1 Day 1	—
Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)	Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)
Change From Baseline in Electrocardiogram Parameter QTcF	From Cycle 1 Day 1 to last dosing day in Cycle 2 (C2D8 for Schedule A, C2D14 for Schedule B, C2D7 for Schedule C).	QT Interval corrected for Fridericia's Formula. Change from baseline is calculated from pre-dose at the indicated timepoints.

Countries

Australia, Canada, France, Spain, United States

Participant flow

Pre-assignment details

83 participants were treated.

Participants by arm

Arm	Count
Part 1 Schedule A - BMS-986158 0.75 mg Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	5
Part 1 Schedule A - BMS-986158 1.25 mg Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	4
Part 1 Schedule A - BMS-986158 2 mg Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	13
Part 1 Schedule A - BMS-986158 3 mg Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	10
Part 1 Schedule A - BMS-986158 4.5 mg Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	13
Part 1 Schedule B - BMS-986158 2 mg Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle	4
Part 1 Schedule B - BMS-986158 3 mg Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle	4
Part 1 Schedule C - BMS-986158 2 mg Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle	6
Part 1 Schedule C - BMS-986158 3 mg Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle	13
Part 1 Schedule C - BMS-986158 4.5 mg Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle	10
Part 2 Schedule A BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle	1
Total	83

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008	FG009	FG010
Overall Study	Adverse event unrelated to study drug	0	0	0	0	2	1	0	1	0	0	0
Overall Study	Disease progression	5	4	13	10	10	3	4	5	13	9	0
Overall Study	Participant request to discontinue	0	0	0	0	0	0	0	0	0	1	0
Overall Study	Study drug toxicity	0	0	0	0	1	0	0	0	0	0	0
Overall Study	Withdrawal by Subject	0	0	0	0	0	0	0	0	0	0	1

Baseline characteristics

Characteristic	Part 1 Schedule A - BMS-986158 1.25 mg	Part 1 Schedule A - BMS-986158 2 mg	Part 1 Schedule A - BMS-986158 3 mg	Part 1 Schedule A - BMS-986158 4.5 mg	Part 1 Schedule B - BMS-986158 2 mg	Part 1 Schedule B - BMS-986158 3 mg	Part 1 Schedule C - BMS-986158 2 mg	Part 1 Schedule C - BMS-986158 3 mg	Part 1 Schedule C - BMS-986158 4.5 mg	Part 1 Schedule A - BMS-986158 0.75 mg	Part 2 Schedule A	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	6 Participants	3 Participants	3 Participants	1 Participants	2 Participants	0 Participants	1 Participants	3 Participants	1 Participants	0 Participants	20 Participants
Age, Categorical Between 18 and 65 years	4 Participants	7 Participants	7 Participants	10 Participants	3 Participants	2 Participants	6 Participants	12 Participants	7 Participants	4 Participants	1 Participants	63 Participants
Age, Continuous	45.0 Years STANDARD_DEVIATION 9.4	63.2 Years STANDARD_DEVIATION 12.1	54.3 Years STANDARD_DEVIATION 16.4	55.5 Years STANDARD_DEVIATION 15.4	61.3 Years STANDARD_DEVIATION 3	68.5 Years STANDARD_DEVIATION 5.4	58.8 Years STANDARD_DEVIATION 2.7	53.6 Years STANDARD_DEVIATION 9.1	58.1 Years STANDARD_DEVIATION 9.9	61.4 Years STANDARD_DEVIATION 7.2	30.0 Years	57.3 Years STANDARD_DEVIATION 12.2
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	0 Participants	3 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants	6 Participants	6 Participants	5 Participants	2 Participants	2 Participants	4 Participants	4 Participants	6 Participants	0 Participants	1 Participants	37 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	3 Participants	7 Participants	4 Participants	8 Participants	2 Participants	2 Participants	1 Participants	8 Participants	3 Participants	5 Participants	0 Participants	43 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants	4 Participants
Race (NIH/OMB) Black or African American	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	4 Participants	1 Participants	0 Participants	0 Participants	8 Participants
Race (NIH/OMB) White	3 Participants	11 Participants	10 Participants	10 Participants	4 Participants	4 Participants	6 Participants	8 Participants	8 Participants	5 Participants	0 Participants	69 Participants
Sex: Female, Male Female	3 Participants	12 Participants	7 Participants	9 Participants	2 Participants	3 Participants	5 Participants	9 Participants	9 Participants	5 Participants	0 Participants	64 Participants
Sex: Female, Male Male	1 Participants	1 Participants	3 Participants	4 Participants	2 Participants	1 Participants	1 Participants	4 Participants	1 Participants	0 Participants	1 Participants	19 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk
deaths Total, all-cause mortality	5 / 5	3 / 4	10 / 13	8 / 10	12 / 13	3 / 4	3 / 4	4 / 6	10 / 13	7 / 10	0 / 1
other Total, other adverse events	5 / 5	4 / 4	12 / 13	10 / 10	13 / 13	4 / 4	4 / 4	6 / 6	13 / 13	9 / 10	1 / 1
serious Total, serious adverse events	3 / 5	3 / 4	7 / 13	7 / 10	9 / 13	2 / 4	2 / 4	4 / 6	5 / 13	3 / 10	0 / 1

Outcome results

Primary

Number of Participants Experiencing Adverse Events

Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths. Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame: From first dose to 30 days following last dose (up to approximately 29 months)

Population: All treated participants

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	3 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants Experiencing Adverse Events	Deaths	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	5 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	3 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants Experiencing Adverse Events	Deaths	1 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	4 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	13 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Deaths	2 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	7 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	7 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	10 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Deaths	4 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	9 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	3 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Deaths	3 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	13 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Deaths	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	4 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	2 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Deaths	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	4 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	2 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	4 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	1 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Deaths	1 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	6 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	13 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Deaths	2 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	5 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	3 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	9 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants Experiencing Adverse Events	Deaths	0 Participants
Part 2 Schedule A	Number of Participants Experiencing Adverse Events	Serious Adverse Events (SAEs)	0 Participants
Part 2 Schedule A	Number of Participants Experiencing Adverse Events	Deaths	0 Participants
Part 2 Schedule A	Number of Participants Experiencing Adverse Events	AEs leading to discontinuation	0 Participants
Part 2 Schedule A	Number of Participants Experiencing Adverse Events	Adverse Events (AEs)	1 Participants

Primary

Number of Participants With Abnormal Hepatic Test Values

Number of participants experiencing abnormal hepatic function, as measured by different parameters. ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal

Time frame: From first dose to 30 days following last dose (up to approximately 29 months)

Population: All treated participants

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	1 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	1 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	1 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	1 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	1 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	2 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	1 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	2 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	4 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	2 Participants
Part 1 Schedule C - BMS-986158 3 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	1 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	1 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	1 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	2 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	1 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	TOTAL BILIRUBIN > 2XULN	1 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 3XULN	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 5XULN	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 1 DAY	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 10XULN	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	ALT OR AST > 20XULN	0 Participants
Part 2 Schedule A	Number of Participants With Abnormal Hepatic Test Values	CONCURRENT ALT OR AST > 3XULN AND BILIRUB > 2XULN WITHIN 30 DAYS	0 Participants

Secondary

Accumulation Index (AI) - Multiple Dose Administration

AI is defined as the ratio of an exposure measure at steady-state to that after the first dose. Reported exposure measures include Cmax, C24 and AUC24. Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Time frame: Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	4.63 Ratio	Geometric Coefficient of Variation 58
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	5.06 Ratio	Geometric Coefficient of Variation 45
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	2.60 Ratio	Geometric Coefficient of Variation 35
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	2.58 Ratio	Geometric Coefficient of Variation 51
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	4.53 Ratio	Geometric Coefficient of Variation 54
Part 1 Schedule A - BMS-986158 0.75 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.89 Ratio	Geometric Coefficient of Variation 20
Part 1 Schedule A - BMS-986158 1.25 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	3.44 Ratio	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 1.25 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.72 Ratio	Geometric Coefficient of Variation 20
Part 1 Schedule A - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	2.91 Ratio	Geometric Coefficient of Variation 27
Part 1 Schedule A - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.76 Ratio	Geometric Coefficient of Variation 34
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.94 Ratio	Geometric Coefficient of Variation 42
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	1.79 Ratio	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	3.46 Ratio	Geometric Coefficient of Variation 33
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	3.18 Ratio	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	1.95 Ratio	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	4.20 Ratio	Geometric Coefficient of Variation 55
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	2.15 Ratio	Geometric Coefficient of Variation 23
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.79 Ratio	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	2.24 Ratio	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	4.45 Ratio	Geometric Coefficient of Variation 30
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	4.33 Ratio	Geometric Coefficient of Variation 39
Part 1 Schedule A - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	5.03 Ratio	Geometric Coefficient of Variation 34
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	1.45 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	1.29 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	2.40 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	2.64 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	2.76 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.35 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	3.05 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	6.35 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	6.23 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	2.37 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	2.78 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	6.85 Ratio	—
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	4.66 Ratio	Geometric Coefficient of Variation 25
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	4.46 Ratio	Geometric Coefficient of Variation 31
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	4.12 Ratio	Geometric Coefficient of Variation 36
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	2.34 Ratio	Geometric Coefficient of Variation 22
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.65 Ratio	Geometric Coefficient of Variation 13
Part 1 Schedule C - BMS-986158 2 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	2.55 Ratio	Geometric Coefficient of Variation 24
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	1.98 Ratio	Geometric Coefficient of Variation 54
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	3.87 Ratio	Geometric Coefficient of Variation 54
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	1.90 Ratio	Geometric Coefficient of Variation 46
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	3.08 Ratio	Geometric Coefficient of Variation 59
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.50 Ratio	Geometric Coefficient of Variation 38
Part 1 Schedule C - BMS-986158 3 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	4.02 Ratio	Geometric Coefficient of Variation 42
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - C24	2.91 Ratio	Geometric Coefficient of Variation 79
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - Cmax	1.59 Ratio	Geometric Coefficient of Variation 47
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - AUC24	3.53 Ratio	Geometric Coefficient of Variation 87
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - C24	1.42 Ratio	Geometric Coefficient of Variation 72
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Parent BMS-986158 - AUC24	1.52 Ratio	Geometric Coefficient of Variation 59
Part 1 Schedule C - BMS-986158 4.5 mg	Accumulation Index (AI) - Multiple Dose Administration	Metabolite BMT-161485 - Cmax	3.21 Ratio	Geometric Coefficient of Variation 64

Secondary

Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Metabolite BMT-161485	35.3 hr	—
Part 1 Schedule A - BMS-986158 0.75 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Parent BMS-986158	33.7 hr	Standard Deviation 1.41
Part 1 Schedule A - BMS-986158 1.25 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Metabolite BMT-161485	50.8 hr	Standard Deviation 6.26
Part 1 Schedule A - BMS-986158 1.25 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Parent BMS-986158	48.7 hr	Standard Deviation 6.66
Part 1 Schedule A - BMS-986158 2 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Parent BMS-986158	54.3 hr	Standard Deviation 19.87
Part 1 Schedule A - BMS-986158 2 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Metabolite BMT-161485	48.8 hr	Standard Deviation 18.78
Part 1 Schedule A - BMS-986158 3 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Parent BMS-986158	42.7 hr	Standard Deviation 19.56
Part 1 Schedule A - BMS-986158 3 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Metabolite BMT-161485	39.4 hr	Standard Deviation 13.8
Part 1 Schedule A - BMS-986158 4.5 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Metabolite BMT-161485	38.7 hr	Standard Deviation 13.66
Part 1 Schedule A - BMS-986158 4.5 mg	Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration	Parent BMS-986158	43.8 hr	Standard Deviation 15.75

Secondary

Apparent Total Body Clearance (CLT/F) - Single Dose Administration

Values are reported only for the parent BMS-986158

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Apparent Total Body Clearance (CLT/F) - Single Dose Administration	5.04 mL/min	Geometric Coefficient of Variation 17
Part 1 Schedule A - BMS-986158 1.25 mg	Apparent Total Body Clearance (CLT/F) - Single Dose Administration	2.97 mL/min	Geometric Coefficient of Variation 18
Part 1 Schedule A - BMS-986158 2 mg	Apparent Total Body Clearance (CLT/F) - Single Dose Administration	3.41 mL/min	Geometric Coefficient of Variation 56
Part 1 Schedule A - BMS-986158 3 mg	Apparent Total Body Clearance (CLT/F) - Single Dose Administration	4.28 mL/min	Geometric Coefficient of Variation 62
Part 1 Schedule A - BMS-986158 4.5 mg	Apparent Total Body Clearance (CLT/F) - Single Dose Administration	3.95 mL/min	Geometric Coefficient of Variation 33

Secondary

Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration

Values are reported only for the parent BMS-986158

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	14.7 Liters	Geometric Coefficient of Variation 21
Part 1 Schedule A - BMS-986158 1.25 mg	Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	12.5 Liters	Geometric Coefficient of Variation 18
Part 1 Schedule A - BMS-986158 2 mg	Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	14.8 Liters	Geometric Coefficient of Variation 27
Part 1 Schedule A - BMS-986158 3 mg	Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	14.4 Liters	Geometric Coefficient of Variation 28
Part 1 Schedule A - BMS-986158 4.5 mg	Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration	14.1 Liters	Geometric Coefficient of Variation 31

Secondary

Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Parent BMS-986158	2479 hr*ng/mL	Geometric Coefficient of Variation 18
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Metabolite BMT-161485	409 hr*ng/mL	—
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Parent BMS-986158	7013 hr*ng/mL	Geometric Coefficient of Variation 17
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Metabolite BMT-161485	892 hr*ng/mL	Geometric Coefficient of Variation 13
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Parent BMS-986158	9775 hr*ng/mL	Geometric Coefficient of Variation 56
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Metabolite BMT-161485	944 hr*ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Metabolite BMT-161485	1128 hr*ng/mL	Geometric Coefficient of Variation 46
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Parent BMS-986158	11677 hr*ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Parent BMS-986158	18974 hr*ng/mL	Geometric Coefficient of Variation 40
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration	Metabolite BMT-161485	2231 hr*ng/mL	Geometric Coefficient of Variation 67

Secondary

Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2150 h*ng/mL	Geometric Coefficient of Variation 15
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	3449 h*ng/mL	Geometric Coefficient of Variation 93
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	314 h*ng/mL	Geometric Coefficient of Variation 32
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1474 h*ng/mL	Geometric Coefficient of Variation 89
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	4961 h*ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	6372 h*ng/mL	Geometric Coefficient of Variation 14
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	691 h*ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	790 h*ng/mL	Geometric Coefficient of Variation 14
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	7612 h*ng/mL	Geometric Coefficient of Variation 71
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	8564 h*ng/mL	Geometric Coefficient of Variation 48
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	992 h*ng/mL	Geometric Coefficient of Variation 65
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1110 h*ng/mL	Geometric Coefficient of Variation 89
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	10452 h*ng/mL	Geometric Coefficient of Variation 50
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	13378 h*ng/mL	Geometric Coefficient of Variation 77
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	1305 h*ng/mL	Geometric Coefficient of Variation 48
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2925 h*ng/mL	Geometric Coefficient of Variation 85
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	2748 h*ng/mL	Geometric Coefficient of Variation 64
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	29517 h*ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	6691 h*ng/mL	Geometric Coefficient of Variation 49
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	19124 h*ng/mL	Geometric Coefficient of Variation 46
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	424 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	6321 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	5202 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1000 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	33978 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	2467 h*ng/mL	Geometric Coefficient of Variation 61
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	7339 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	25852 h*ng/mL	Geometric Coefficient of Variation 41
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	10931 h*ng/mL	Geometric Coefficient of Variation 43
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	5022 h*ng/mL	Geometric Coefficient of Variation 62
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	19868 h*ng/mL	Geometric Coefficient of Variation 45
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	1895 h*ng/mL	Geometric Coefficient of Variation 58
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	3458 h*ng/mL	Geometric Coefficient of Variation 96
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	11493 h*ng/mL	Geometric Coefficient of Variation 54
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	1219 h*ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	18266 h*ng/mL	Geometric Coefficient of Variation 97
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 day 1	2645 h*ng/mL	Geometric Coefficient of Variation 77
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	17220 h*ng/mL	Geometric Coefficient of Variation 84
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	5719 h*ng/mL	Geometric Coefficient of Variation 134
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	19995 h*ng/mL	Geometric Coefficient of Variation 135

Secondary

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	98.2 h*ng/mL	Geometric Coefficient of Variation 34
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	2716 h*ng/mL	Geometric Coefficient of Variation 51
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	550 h*ng/mL	Geometric Coefficient of Variation 81
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1027 h*ng/mL	Geometric Coefficient of Variation 16
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	188 h*ng/mL	Geometric Coefficient of Variation 11
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2309 h*ng/mL	Geometric Coefficient of Variation 13
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	3852 h*ng/mL	—
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	500 h*ng/mL	—
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	290 h*ng/mL	Geometric Coefficient of Variation 22
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	3610 h*ng/mL	Geometric Coefficient of Variation 22
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1746 h*ng/mL	Geometric Coefficient of Variation 64
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	9817 h*ng/mL	Geometric Coefficient of Variation 56
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	404 h*ng/mL	Geometric Coefficient of Variation 39
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	4942 h*ng/mL	Geometric Coefficient of Variation 43
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	14551 h*ng/mL	Geometric Coefficient of Variation 32
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	6786 h*ng/mL	Geometric Coefficient of Variation 24
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	560 h*ng/mL	Geometric Coefficient of Variation 42
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2649 h*ng/mL	Geometric Coefficient of Variation 48
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	3430 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2358 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	505 h*ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	191 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	439 h*ng/mL	Geometric Coefficient of Variation 52
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2551 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	13305 h*ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	6921 h*ng/mL	Geometric Coefficient of Variation 28
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1765 h*ng/mL	Geometric Coefficient of Variation 51
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	367 h*ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	3660 h*ng/mL	Geometric Coefficient of Variation 27
Part 1 Schedule C - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	8561 h*ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	4468 h*ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	8637 h*ng/mL	Geometric Coefficient of Variation 71
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	337 h*ng/mL	Geometric Coefficient of Variation 46
Part 1 Schedule C - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1299 h*ng/mL	Geometric Coefficient of Variation 63
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	11286 h*ng/mL	Geometric Coefficient of Variation 104
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	7418 h*ng/mL	Geometric Coefficient of Variation 43
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2616 h*ng/mL	Geometric Coefficient of Variation 102
Part 1 Schedule C - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	741 h*ng/mL	Geometric Coefficient of Variation 38

Secondary

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Parent BMS-986158	1027 hr*ng/mL	Geometric Coefficient of Variation 16
Part 1 Schedule A - BMS-986158 0.75 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Metabolite BMT-161485	98.2 hr*ng/mL	Geometric Coefficient of Variation 34
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Parent BMS-986158	2309 hr*ng/mL	Geometric Coefficient of Variation 13
Part 1 Schedule A - BMS-986158 1.25 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Metabolite BMT-161485	188 hr*ng/mL	Geometric Coefficient of Variation 11
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Parent BMS-986158	3533 hr*ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule A - BMS-986158 2 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Metabolite BMT-161485	310 hr*ng/mL	Geometric Coefficient of Variation 35
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Metabolite BMT-161485	377 hr*ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule A - BMS-986158 3 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Parent BMS-986158	4989 hr*ng/mL	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Parent BMS-986158	7039 hr*ng/mL	Geometric Coefficient of Variation 34
Part 1 Schedule A - BMS-986158 4.5 mg	Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration	Metabolite BMT-161485	629 hr*ng/mL	Geometric Coefficient of Variation 41

Secondary

Best Overall Response (BOR)

BOR, as assessed by the investigator, is defined as the best response designation, recorded between the dates of first dose and the date of first objectively documented progression (per RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies or PCWG3 for prostate cancer) or the date of subsequent therapy, whichever occurs first.

Time frame: From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)

Population: All treated participants

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Schedule A - BMS-986158 0.75 mg	Best Overall Response (BOR)	Unable to determine	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Best Overall Response (BOR)	Stable Disease	1 Participants
Part 1 Schedule A - BMS-986158 0.75 mg	Best Overall Response (BOR)	Progressive Disease	4 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Best Overall Response (BOR)	Progressive Disease	2 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Best Overall Response (BOR)	Stable Disease	1 Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Best Overall Response (BOR)	Unable to determine	1 Participants
Part 1 Schedule A - BMS-986158 2 mg	Best Overall Response (BOR)	Stable Disease	2 Participants
Part 1 Schedule A - BMS-986158 2 mg	Best Overall Response (BOR)	Unable to determine	3 Participants
Part 1 Schedule A - BMS-986158 2 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule A - BMS-986158 2 mg	Best Overall Response (BOR)	Progressive Disease	8 Participants
Part 1 Schedule A - BMS-986158 3 mg	Best Overall Response (BOR)	Progressive Disease	7 Participants
Part 1 Schedule A - BMS-986158 3 mg	Best Overall Response (BOR)	Stable Disease	1 Participants
Part 1 Schedule A - BMS-986158 3 mg	Best Overall Response (BOR)	Unable to determine	2 Participants
Part 1 Schedule A - BMS-986158 3 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule A - BMS-986158 3 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Best Overall Response (BOR)	Unable to determine	2 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Best Overall Response (BOR)	Stable Disease	7 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Best Overall Response (BOR)	Progressive Disease	3 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Best Overall Response (BOR)	Partial Response	1 Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Best Overall Response (BOR)	Stable Disease	2 Participants
Part 1 Schedule B - BMS-986158 2 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule B - BMS-986158 2 mg	Best Overall Response (BOR)	Progressive Disease	2 Participants
Part 1 Schedule B - BMS-986158 2 mg	Best Overall Response (BOR)	Unable to determine	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Best Overall Response (BOR)	Stable Disease	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Best Overall Response (BOR)	Unable to determine	1 Participants
Part 1 Schedule B - BMS-986158 3 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule B - BMS-986158 3 mg	Best Overall Response (BOR)	Progressive Disease	2 Participants
Part 1 Schedule C - BMS-986158 2 mg	Best Overall Response (BOR)	Stable Disease	1 Participants
Part 1 Schedule C - BMS-986158 2 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule C - BMS-986158 2 mg	Best Overall Response (BOR)	Unable to determine	3 Participants
Part 1 Schedule C - BMS-986158 2 mg	Best Overall Response (BOR)	Progressive Disease	2 Participants
Part 1 Schedule C - BMS-986158 2 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Best Overall Response (BOR)	Stable Disease	4 Participants
Part 1 Schedule C - BMS-986158 3 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Best Overall Response (BOR)	Progressive Disease	9 Participants
Part 1 Schedule C - BMS-986158 3 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule C - BMS-986158 3 mg	Best Overall Response (BOR)	Unable to determine	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Best Overall Response (BOR)	Complete Response	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Best Overall Response (BOR)	Progressive Disease	4 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Best Overall Response (BOR)	Unable to determine	2 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Best Overall Response (BOR)	Partial Response	0 Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Best Overall Response (BOR)	Stable Disease	4 Participants
Part 2 Schedule A	Best Overall Response (BOR)	Progressive Disease	0 Participants
Part 2 Schedule A	Best Overall Response (BOR)	Stable Disease	0 Participants
Part 2 Schedule A	Best Overall Response (BOR)	Partial Response	1 Participants
Part 2 Schedule A	Best Overall Response (BOR)	Complete Response	0 Participants
Part 2 Schedule A	Best Overall Response (BOR)	Unable to determine	0 Participants

Secondary

Change From Baseline in Electrocardiogram Parameter QTcF

QT Interval corrected for Fridericia's Formula. Change from baseline is calculated from pre-dose at the indicated timepoints.

Time frame: From Cycle 1 Day 1 to last dosing day in Cycle 2 (C2D8 for Schedule A, C2D14 for Schedule B, C2D7 for Schedule C).

Population: All treated participants with available measurements at the indicated timepoints. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-6.8 msec	Standard Deviation 11.63
Part 1 Schedule A - BMS-986158 1.25 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-5.3 msec	—
Part 1 Schedule A - BMS-986158 2 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-3.3 msec	Standard Deviation 22.48
Part 1 Schedule A - BMS-986158 3 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-5.4 msec	Standard Deviation 18.45
Part 1 Schedule A - BMS-986158 4.5 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-10.2 msec	Standard Deviation 22.43
Part 1 Schedule B - BMS-986158 2 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-10.7 msec	Standard Deviation 15.1
Part 1 Schedule B - BMS-986158 3 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-16.7 msec	—
Part 1 Schedule C - BMS-986158 2 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-7.7 msec	Standard Deviation 10.98
Part 1 Schedule C - BMS-986158 3 mg	Change From Baseline in Electrocardiogram Parameter QTcF	14.3 msec	Standard Deviation 14.03
Part 1 Schedule C - BMS-986158 4.5 mg	Change From Baseline in Electrocardiogram Parameter QTcF	-0.6 msec	Standard Deviation 10.75

Secondary

Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	33.5 ng/mL	Geometric Coefficient of Variation 18
Part 1 Schedule A - BMS-986158 0.75 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	87.9 ng/mL	Geometric Coefficient of Variation 63
Part 1 Schedule A - BMS-986158 0.75 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	4.85 ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 0.75 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	16.4 ng/mL	Geometric Coefficient of Variation 91
Part 1 Schedule A - BMS-986158 1.25 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	22.3 ng/mL	Geometric Coefficient of Variation 22
Part 1 Schedule A - BMS-986158 1.25 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	67.4 ng/mL	Geometric Coefficient of Variation 12
Part 1 Schedule A - BMS-986158 1.25 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	7.92 ng/mL	Geometric Coefficient of Variation 8
Part 1 Schedule A - BMS-986158 1.25 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	116 ng/mL	—
Part 1 Schedule A - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	33.7 ng/mL	Geometric Coefficient of Variation 55
Part 1 Schedule A - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	108 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	12.0 ng/mL	Geometric Coefficient of Variation 37
Part 1 Schedule A - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	143 ng/mL	Geometric Coefficient of Variation 50
Part 1 Schedule A - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	280 ng/mL	Geometric Coefficient of Variation 64
Part 1 Schedule A - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	18.8 ng/mL	Geometric Coefficient of Variation 40
Part 1 Schedule A - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	54.0 ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule A - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	27.0 ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule A - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	461 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	89.6 ng/mL	Geometric Coefficient of Variation 55
Part 1 Schedule A - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	210 ng/mL	Geometric Coefficient of Variation 32
Part 1 Schedule B - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	5.23 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	85.1 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	66.1 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	14.4 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	463 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	19.0 ng/mL	Geometric Coefficient of Variation 42
Part 1 Schedule B - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	104 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	232 ng/mL	Geometric Coefficient of Variation 30
Part 1 Schedule C - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	112 ng/mL	Geometric Coefficient of Variation 33
Part 1 Schedule C - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	69.4 ng/mL	Geometric Coefficient of Variation 62
Part 1 Schedule C - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	276 ng/mL	Geometric Coefficient of Variation 45
Part 1 Schedule C - BMS-986158 2 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	16.3 ng/mL	Geometric Coefficient of Variation 37
Part 1 Schedule C - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	47.8 ng/mL	Geometric Coefficient of Variation 74
Part 1 Schedule C - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	125 ng/mL	Geometric Coefficient of Variation 43
Part 1 Schedule C - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	12.9 ng/mL	Geometric Coefficient of Variation 58
Part 1 Schedule C - BMS-986158 3 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	244 ng/mL	Geometric Coefficient of Variation 93
Part 1 Schedule C - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	29.1 ng/mL	Geometric Coefficient of Variation 53
Part 1 Schedule C - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	185 ng/mL	Geometric Coefficient of Variation 68
Part 1 Schedule C - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	84.5 ng/mL	Geometric Coefficient of Variation 120
Part 1 Schedule C - BMS-986158 4.5 mg	Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	263 ng/mL	Geometric Coefficient of Variation 131

Secondary

Duration of Response (DOR)

DOR is defined as the time between the date of first response and the date of the first objectively documented disease progression (as determined by RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies, or PCWG3 (including PSA assessments) for prostate cancer \[CRPC or NEPC\]), or death due to any cause, whichever occurs first.

Time frame: From date of first response to date of first objectively documented disease progression or death (up to approximately 42 weeks)

Population: All participants who achieved a Complete Response (CR) or Partial Response (PR)

Arm	Measure	Value (MEAN)
Part 1 Schedule A - BMS-986158 4.5 mg	Duration of Response (DOR)	22.3 Weeks
Part 2 Schedule A	Duration of Response (DOR)	42.4 Weeks

Secondary

Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Time frame: Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	36.0 Hours	Standard Deviation 15.99
Part 1 Schedule A - BMS-986158 0.75 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	80.9 Hours	Standard Deviation 40.42
Part 1 Schedule A - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	25.7 Hours	Standard Deviation 14.86
Part 1 Schedule A - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	72.1 Hours	Standard Deviation 47.11
Part 1 Schedule A - BMS-986158 4.5 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	27.3 Hours	Standard Deviation 8.72
Part 1 Schedule A - BMS-986158 4.5 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	80.4 Hours	Standard Deviation 29.59
Part 1 Schedule B - BMS-986158 2 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	14.4 Hours	—
Part 1 Schedule B - BMS-986158 2 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	35.2 Hours	—
Part 1 Schedule B - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	105 Hours	—
Part 1 Schedule B - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	37.3 Hours	—
Part 1 Schedule C - BMS-986158 2 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	72.7 Hours	Standard Deviation 19.42
Part 1 Schedule C - BMS-986158 2 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	31.6 Hours	Standard Deviation 10.48
Part 1 Schedule C - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	27.3 Hours	Standard Deviation 15.15
Part 1 Schedule C - BMS-986158 3 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	63.5 Hours	Standard Deviation 39.53
Part 1 Schedule C - BMS-986158 4.5 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Metabolite BMT-161485	72.8 Hours	Standard Deviation 74.17
Part 1 Schedule C - BMS-986158 4.5 mg	Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration	Parent BMS-986158	27.6 Hours	Standard Deviation 19.11

Secondary

Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	68.8 ng/mL	Geometric Coefficient of Variation 23
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	136 ng/mL	Geometric Coefficient of Variation 43
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	5.00 ng/mL	Geometric Coefficient of Variation 30
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	25.8 ng/mL	Geometric Coefficient of Variation 82
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	284 ng/mL	Geometric Coefficient of Variation 16
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	175 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	31.0 ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	10.0 ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	442 ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	260 ng/mL	Geometric Coefficient of Variation 20
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	16.9 ng/mL	Geometric Coefficient of Variation 32
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	49.4 ng/mL	Geometric Coefficient of Variation 46
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	328 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	624 ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	22.5 ng/mL	Geometric Coefficient of Variation 38
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	83.3 ng/mL	Geometric Coefficient of Variation 57
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	30.0 ng/mL	Geometric Coefficient of Variation 41
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	898 ng/mL	Geometric Coefficient of Variation 39
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	126 ng/mL	Geometric Coefficient of Variation 50
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	478 ng/mL	Geometric Coefficient of Variation 24
Part 1 Schedule B - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	13.6 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	279 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	207 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	32.7 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	855 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	26.3 ng/mL	Geometric Coefficient of Variation 63
Part 1 Schedule B - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	127 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	481 ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule C - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	295 ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule C - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	80.7 ng/mL	Geometric Coefficient of Variation 53
Part 1 Schedule C - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	520 ng/mL	Geometric Coefficient of Variation 34
Part 1 Schedule C - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	21.1 ng/mL	Geometric Coefficient of Variation 35
Part 1 Schedule C - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	64.5 ng/mL	Geometric Coefficient of Variation 55
Part 1 Schedule C - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	370 ng/mL	Geometric Coefficient of Variation 22
Part 1 Schedule C - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	19.4 ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule C - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	588 ng/mL	Geometric Coefficient of Variation 47
Part 1 Schedule C - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	45.5 ng/mL	Geometric Coefficient of Variation 32
Part 1 Schedule C - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 Day 1	567 ng/mL	Geometric Coefficient of Variation 24
Part 1 Schedule C - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	146 ng/mL	Geometric Coefficient of Variation 83
Part 1 Schedule C - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	901 ng/mL	Geometric Coefficient of Variation 62

Secondary

Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Parent BMS-986158	68.8 ng/mL	Geometric Coefficient of Variation 23
Part 1 Schedule A - BMS-986158 0.75 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Metabolite BMT-161485	5.00 ng/mL	Geometric Coefficient of Variation 30
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Parent BMS-986158	175 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 1.25 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Metabolite BMT-161485	10.0 ng/mL	Geometric Coefficient of Variation 29
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Parent BMS-986158	269 ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule A - BMS-986158 2 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Metabolite BMT-161485	18.2 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Metabolite BMT-161485	21.6 ng/mL	Geometric Coefficient of Variation 47
Part 1 Schedule A - BMS-986158 3 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Parent BMS-986158	368 ng/mL	Geometric Coefficient of Variation 30
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Parent BMS-986158	513 ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule A - BMS-986158 4.5 mg	Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration	Metabolite BMT-161485	35.6 ng/mL	Geometric Coefficient of Variation 41

Secondary

Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are reported only for the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	73.7 ng/mL	Geometric Coefficient of Variation 45
Part 1 Schedule A - BMS-986158 0.75 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	16.4 ng/mL	Geometric Coefficient of Variation 91
Part 1 Schedule A - BMS-986158 1.25 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	141 ng/mL	Geometric Coefficient of Variation 17
Part 1 Schedule A - BMS-986158 1.25 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	22.3 ng/mL	Geometric Coefficient of Variation 22
Part 1 Schedule A - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	208 ng/mL	Geometric Coefficient of Variation 53
Part 1 Schedule A - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	33.7 ng/mL	Geometric Coefficient of Variation 55
Part 1 Schedule A - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	227 ng/mL	Geometric Coefficient of Variation 76
Part 1 Schedule A - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	54.0 ng/mL	Geometric Coefficient of Variation 73
Part 1 Schedule A - BMS-986158 4.5 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	89.6 ng/mL	Geometric Coefficient of Variation 55
Part 1 Schedule A - BMS-986158 4.5 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	428 ng/mL	Geometric Coefficient of Variation 41
Part 1 Schedule B - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	14.4 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	85.1 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	79.5 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	435 ng/mL	—
Part 1 Schedule C - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	270 ng/mL	Geometric Coefficient of Variation 42
Part 1 Schedule C - BMS-986158 2 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	59.7 ng/mL	Geometric Coefficient of Variation 54
Part 1 Schedule C - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	238 ng/mL	Geometric Coefficient of Variation 94
Part 1 Schedule C - BMS-986158 3 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	44.2 ng/mL	Geometric Coefficient of Variation 74
Part 1 Schedule C - BMS-986158 4.5 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	253 ng/mL	Geometric Coefficient of Variation 125
Part 1 Schedule C - BMS-986158 4.5 mg	Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	71.1 ng/mL	Geometric Coefficient of Variation 115

Secondary

Objective Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR)

Time frame: From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)

Population: All treated participants

Arm	Measure	Value (NUMBER)
Part 1 Schedule A - BMS-986158 0.75 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule A - BMS-986158 1.25 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule A - BMS-986158 2 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule A - BMS-986158 3 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule A - BMS-986158 4.5 mg	Objective Response Rate (ORR)	7.7 Percent of Participants
Part 1 Schedule B - BMS-986158 2 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule B - BMS-986158 3 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule C - BMS-986158 2 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule C - BMS-986158 3 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 1 Schedule C - BMS-986158 4.5 mg	Objective Response Rate (ORR)	0 Percent of Participants
Part 2 Schedule A	Objective Response Rate (ORR)	100.0 Percent of Participants

Secondary

Progression Free Survival (PFS)

PFS is defined as the time from the first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause.

Time frame: From first dose to date of first objectively documented disease progression or death (up to approximately 28 months)

Population: All treated participants.

Arm	Measure	Value (MEDIAN)
Part 1 Schedule A - BMS-986158 0.75 mg	Progression Free Survival (PFS)	4.57 Weeks
Part 1 Schedule A - BMS-986158 1.25 mg	Progression Free Survival (PFS)	9.71 Weeks
Part 1 Schedule A - BMS-986158 2 mg	Progression Free Survival (PFS)	7.57 Weeks
Part 1 Schedule A - BMS-986158 3 mg	Progression Free Survival (PFS)	7.43 Weeks
Part 1 Schedule A - BMS-986158 4.5 mg	Progression Free Survival (PFS)	13.79 Weeks
Part 1 Schedule B - BMS-986158 2 mg	Progression Free Survival (PFS)	24.29 Weeks
Part 1 Schedule B - BMS-986158 3 mg	Progression Free Survival (PFS)	6.57 Weeks
Part 1 Schedule C - BMS-986158 2 mg	Progression Free Survival (PFS)	8.29 Weeks
Part 1 Schedule C - BMS-986158 3 mg	Progression Free Survival (PFS)	8.43 Weeks
Part 1 Schedule C - BMS-986158 4.5 mg	Progression Free Survival (PFS)	9.14 Weeks
Part 2 Schedule A	Progression Free Survival (PFS)	NA Weeks

Secondary

Progression Free Survival Rate (PFSR)

PFSR is defined as the percentage of participants who remain progression free and surviving at the specified timepoints (12 weeks, 24 weeks, and 48 weeks). Reported values are estimates derived from Kaplan-Meier analyses

Time frame: From first dose to 12 weeks, to 24 weeks, and to 48 weeks after first dose

Population: All treated participants.

Arm	Measure	Group	Value (NUMBER)
Part 1 Schedule A - BMS-986158 0.75 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 0.75 mg	Progression Free Survival Rate (PFSR)	12 weeks	20.0 Percent of participants
Part 1 Schedule A - BMS-986158 0.75 mg	Progression Free Survival Rate (PFSR)	24 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 1.25 mg	Progression Free Survival Rate (PFSR)	24 weeks	33.3 Percent of participants
Part 1 Schedule A - BMS-986158 1.25 mg	Progression Free Survival Rate (PFSR)	12 weeks	33.3 Percent of participants
Part 1 Schedule A - BMS-986158 1.25 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	24 weeks	9.1 Percent of participants
Part 1 Schedule A - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	12 weeks	27.3 Percent of participants
Part 1 Schedule A - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	12 weeks	11.1 Percent of participants
Part 1 Schedule A - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	24 weeks	11.1 Percent of participants
Part 1 Schedule A - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	24 weeks	30.0 Percent of participants
Part 1 Schedule A - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule A - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	12 weeks	50.0 Percent of participants
Part 1 Schedule B - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	48 weeks	25.0 Percent of participants
Part 1 Schedule B - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	12 weeks	50.0 Percent of participants
Part 1 Schedule B - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	24 weeks	50.0 Percent of participants
Part 1 Schedule B - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	12 weeks	33.3 Percent of participants
Part 1 Schedule B - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	24 weeks	33.3 Percent of participants
Part 1 Schedule B - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule C - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 1 Schedule C - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	24 weeks	0.0 Percent of participants
Part 1 Schedule C - BMS-986158 2 mg	Progression Free Survival Rate (PFSR)	12 weeks	20.0 Percent of participants
Part 1 Schedule C - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	48 weeks	9.2 Percent of participants
Part 1 Schedule C - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	12 weeks	27.5 Percent of participants
Part 1 Schedule C - BMS-986158 3 mg	Progression Free Survival Rate (PFSR)	24 weeks	18.3 Percent of participants
Part 1 Schedule C - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	24 weeks	0.0 Percent of participants
Part 1 Schedule C - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	12 weeks	45.7 Percent of participants
Part 1 Schedule C - BMS-986158 4.5 mg	Progression Free Survival Rate (PFSR)	48 weeks	0.0 Percent of participants
Part 2 Schedule A	Progression Free Survival Rate (PFSR)	24 weeks	100.0 Percent of participants
Part 2 Schedule A	Progression Free Survival Rate (PFSR)	12 weeks	100.0 Percent of participants
Part 2 Schedule A	Progression Free Survival Rate (PFSR)	48 weeks	100.0 Percent of participants

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration

Time frame: Cycle 1 Day 1

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.177 Ratio	—
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.131 Ratio	Standard Deviation 0.0426
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.120 Ratio	Standard Deviation 0.0286
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.158 Ratio	Standard Deviation 0.0307
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.164 Ratio	Standard Deviation 0.0809
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.080 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.106 Ratio	—
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.139 Ratio	Standard Deviation 0.0401
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.103 Ratio	Standard Deviation 0.0357
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration	0.184 Ratio	Standard Deviation 0.0947

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.154 Ratio	Standard Deviation 0.0504
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.247 Ratio	Standard Deviation 0.1
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.141 Ratio	Standard Deviation 0.0248
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.127 Ratio	Standard Deviation 0.0369
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.150 Ratio	Standard Deviation 0.0377
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.125 Ratio	Standard Deviation 0.0262
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.152 Ratio	Standard Deviation 0.0572
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.234 Ratio	Standard Deviation 0.0787
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.233 Ratio	Standard Deviation 0.0558
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.151 Ratio	Standard Deviation 0.0558
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.158 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.081 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.099 Ratio	Standard Deviation 0.0279
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.216 Ratio	—
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.274 Ratio	Standard Deviation 0.1184
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.182 Ratio	Standard Deviation 0.0632
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.203 Ratio	Standard Deviation 0.0788
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.114 Ratio	Standard Deviation 0.0473
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Cycle 1 Day 1	0.170 Ratio	Standard Deviation 0.0821
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration	Latest timepoint	0.320 Ratio	Standard Deviation 0.1552

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.099 Ratio	Standard Deviation 0.029
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.213 Ratio	Standard Deviation 0.0786
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.130 Ratio	—
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.081 Ratio	Standard Deviation 0.0055
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.086 Ratio	Standard Deviation 0.0208
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.097 Ratio	Standard Deviation 0.0425
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.192 Ratio	Standard Deviation 0.0697
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.187 Ratio	Standard Deviation 0.0475
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.087 Ratio	Standard Deviation 0.0347
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.147 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.081 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.192 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.066 Ratio	Standard Deviation 0.0221
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.102 Ratio	Standard Deviation 0.0178
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.218 Ratio	Standard Deviation 0.077
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.080 Ratio	Standard Deviation 0.0283
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.160 Ratio	Standard Deviation 0.0561
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Latest timepoint	0.253 Ratio	Standard Deviation 0.1151
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration	Cycle 1 Day 1	0.108 Ratio	Standard Deviation 0.0445

Secondary

Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.073 Ratio	Standard Deviation 0.0104
Part 1 Schedule A - BMS-986158 0.75 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.179 Ratio	Standard Deviation 0.0726
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.057 Ratio	Standard Deviation 0.0052
Part 1 Schedule A - BMS-986158 1.25 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.112 Ratio	Standard Deviation 0.0329
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.068 Ratio	Standard Deviation 0.0204
Part 1 Schedule A - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.115 Ratio	Standard Deviation 0.029
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.078 Ratio	Standard Deviation 0.0268
Part 1 Schedule A - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.144 Ratio	Standard Deviation 0.0528
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.142 Ratio	Standard Deviation 0.026
Part 1 Schedule A - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.068 Ratio	Standard Deviation 0.0303
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.117 Ratio	—
Part 1 Schedule B - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.066 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.149 Ratio	—
Part 1 Schedule B - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.059 Ratio	Standard Deviation 0.0247
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.077 Ratio	Standard Deviation 0.0373
Part 1 Schedule C - BMS-986158 2 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.163 Ratio	Standard Deviation 0.0536
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.056 Ratio	Standard Deviation 0.0187
Part 1 Schedule C - BMS-986158 3 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.115 Ratio	Standard Deviation 0.0371
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Cycle 1 Day 1	0.083 Ratio	Standard Deviation 0.0209
Part 1 Schedule C - BMS-986158 4.5 mg	Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration	Latest timepoint	0.173 Ratio	Standard Deviation 0.0576

Secondary

Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

Time frame: From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

Population: All treated participants with available measurements

Arm	Measure	Group	Value (MEDIAN)
Part 1 Schedule A - BMS-986158 0.75 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Parent BMS-986158	4.00 Hours
Part 1 Schedule A - BMS-986158 0.75 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Metabolite BMT-161485	24.0 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Parent BMS-986158	1.00 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Metabolite BMT-161485	2.00 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Parent BMS-986158	1.04 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Metabolite BMT-161485	6.00 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Metabolite BMT-161485	3.03 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Parent BMS-986158	1.02 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Parent BMS-986158	2.02 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration	Metabolite BMT-161485	6.27 Hours

Secondary

Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration

Time frame: From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (MEDIAN)
Part 1 Schedule A - BMS-986158 0.75 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	4.00 Hours
Part 1 Schedule A - BMS-986158 0.75 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	3.14 Hours
Part 1 Schedule A - BMS-986158 0.75 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	24.0 Hours
Part 1 Schedule A - BMS-986158 0.75 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	24.0 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	1.50 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1.00 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	4.00 Hours
Part 1 Schedule A - BMS-986158 1.25 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	2.00 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	2.00 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2.00 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	5.08 Hours
Part 1 Schedule A - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2.07 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2.00 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	2.01 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	23.9 Hours
Part 1 Schedule A - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	2.01 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	15.1 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	2.00 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	4.00 Hours
Part 1 Schedule A - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2.04 Hours
Part 1 Schedule B - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	1.00 Hours
Part 1 Schedule B - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	1.00 Hours
Part 1 Schedule B - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1.00 Hours
Part 1 Schedule B - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1.00 Hours
Part 1 Schedule B - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	1.00 Hours
Part 1 Schedule B - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	1.52 Hours
Part 1 Schedule B - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	1.00 Hours
Part 1 Schedule B - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1.03 Hours
Part 1 Schedule C - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1.00 Hours
Part 1 Schedule C - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	4.08 Hours
Part 1 Schedule C - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	1.00 Hours
Part 1 Schedule C - BMS-986158 2 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	14.9 Hours
Part 1 Schedule C - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	4.00 Hours
Part 1 Schedule C - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	1.00 Hours
Part 1 Schedule C - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	2.02 Hours
Part 1 Schedule C - BMS-986158 3 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	1.66 Hours
Part 1 Schedule C - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 - Cycle 1 Day 1	6.27 Hours
Part 1 Schedule C - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Cycle 1 day 1	2.02 Hours
Part 1 Schedule C - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Metabolite BMT-161485 -Latest timepoint	4.00 Hours
Part 1 Schedule C - BMS-986158 4.5 mg	Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration	Parent BMS-986158 - Latest timepoint	2.00 Hours

Secondary

Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485. Values are also reported separately for the first and last collection

Time frame: From Cycle (C)2 Day (D)2 to C2D5 (Schedule A) or from C2D14 to C4D8 (Schedule B) or from C2D7 to C8D8 (Schedule C)

Population: All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1 Schedule A - BMS-986158 0.75 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	35.7 ng/mL	Geometric Coefficient of Variation 25
Part 1 Schedule A - BMS-986158 0.75 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	87.9 ng/mL	Geometric Coefficient of Variation 63
Part 1 Schedule A - BMS-986158 0.75 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	7.78 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 0.75 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	25.8 ng/mL	Geometric Coefficient of Variation 82
Part 1 Schedule A - BMS-986158 1.25 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	9.42 ng/mL	Geometric Coefficient of Variation 19
Part 1 Schedule A - BMS-986158 1.25 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	79.6 ng/mL	Geometric Coefficient of Variation 10
Part 1 Schedule A - BMS-986158 1.25 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	116 ng/mL	—
Part 1 Schedule A - BMS-986158 1.25 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	20.1 ng/mL	—
Part 1 Schedule A - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	11.4 ng/mL	Geometric Coefficient of Variation 51
Part 1 Schedule A - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	142 ng/mL	Geometric Coefficient of Variation 51
Part 1 Schedule A - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	138 ng/mL	Geometric Coefficient of Variation 48
Part 1 Schedule A - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	65.8 ng/mL	Geometric Coefficient of Variation 63
Part 1 Schedule A - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	22.2 ng/mL	Geometric Coefficient of Variation 48
Part 1 Schedule A - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	280 ng/mL	Geometric Coefficient of Variation 64
Part 1 Schedule A - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	257 ng/mL	Geometric Coefficient of Variation 27
Part 1 Schedule A - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	461 ng/mL	Geometric Coefficient of Variation 36
Part 1 Schedule A - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	36.5 ng/mL	Geometric Coefficient of Variation 44
Part 1 Schedule A - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	108 ng/mL	Geometric Coefficient of Variation 47
Part 1 Schedule B - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	16.9 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	289 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	109 ng/mL	—
Part 1 Schedule B - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	36.4 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	79.5 ng/mL	—
Part 1 Schedule B - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	435 ng/mL	—
Part 1 Schedule C - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	242 ng/mL	Geometric Coefficient of Variation 58
Part 1 Schedule C - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	51.2 ng/mL	Geometric Coefficient of Variation 68
Part 1 Schedule C - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	69.1 ng/mL	—
Part 1 Schedule C - BMS-986158 2 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	10.8 ng/mL	—
Part 1 Schedule C - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	49.4 ng/mL	Geometric Coefficient of Variation 81
Part 1 Schedule C - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 -Last collection	370 ng/mL	—
Part 1 Schedule C - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - Last collection	24.5 ng/mL	—
Part 1 Schedule C - BMS-986158 3 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	282 ng/mL	Geometric Coefficient of Variation 98
Part 1 Schedule C - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Parent BMS-986158 - First collection	284 ng/mL	Geometric Coefficient of Variation 119
Part 1 Schedule C - BMS-986158 4.5 mg	Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration	Metabolite BMT-161485 - First collection	75.3 ng/mL	Geometric Coefficient of Variation 110

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026

Study of BMS-986158 in Subjects With Select Advanced Cancers

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants Experiencing Adverse Events

Number of Participants With Abnormal Hepatic Test Values

Accumulation Index (AI) - Multiple Dose Administration

Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration

Apparent Total Body Clearance (CLT/F) - Single Dose Administration

Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration

Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration

Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration

Best Overall Response (BOR)

Change From Baseline in Electrocardiogram Parameter QTcF

Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration

Duration of Response (DOR)

Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration

Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration

Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration

Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration

Objective Response Rate (ORR)

Progression Free Survival (PFS)

Progression Free Survival Rate (PFSR)

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration

Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration

Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration

Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration

Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration